Skip to main content
BioPorto enters distribution deal with Roche for NGAL test

Denmark-based in vitro diagnostics company BioPorto signed an agreement with Roche Holding to globally distribute its CE-marked neutrophil gelatinase-associated lipocalin test for use on Cobas c 502 and Cobas c 501 analyzers to diagnose acute kidney injury; terms were undisclosed. Clinical studies are being conducted by BioPorto as it expects to receive FDA approval for the test later this year.

Full Story: